Estimating the lost benefits of antiretroviral drug use in South Africa.

  title={Estimating the lost benefits of antiretroviral drug use in South Africa.},
  author={Pride Chigwedere and George R. Seage and Sofia Gruskin and Tun‐Hou Lee and Max Essex},
  journal={Journal of acquired immune deficiency syndromes},
  volume={49 4},
South Africa is one of the countries most severely affected by HIV/AIDS. At the peak of the epidemic, the government, going against consensus scientific opinion, argued that HIV was not the cause of AIDS and that antiretroviral (ARV) drugs were not useful for patients and declined to accept freely donated nevirapine and grants from the Global Fund. Using modeling, we compared the number of persons who received ARVs for treatment and prevention of mother-to-child HIV transmission between 2000… 

The adequacy of policy responses to the treatment needs of South Africans living with HIV (1999-2008): a case study

  • J. Gow
  • Medicine, Political Science
    Journal of the International AIDS Society
  • 2009
The movement towards a national ART programme in South Africa was an ambitious undertaking, the likes of which had not been contemplated before in public health in Africa, but it failed because of lack of political commitment and inadequate public health system capacity.

Prevention of mother-to-child transmission in South Africa: an ever-changing landscape

The evolution of the HIV epidemic in South Africa is discussed, and a historical overview of the struggle to establish a national PMTCT is given, and the impact of delaying PMT CT and treatment programmes on infant and maternal health is given.

Provision of Antiretroviral Therapy in South Africa: The Nuts and Bolts

South Africa is a test case of whether a large-scale public health programme can boast of success in the face of numerous other health-system challenges and challenges include increasing detection within communities, linkage and retention in care, while strengthening operational support functions.

HIV/AIDS in South Africa: how many people died from the disease between 1997 and 2010?

Empirically based estimates confirm the considerable loss of life from HIV/AIDS and should be used for calibrating models of the AIDS epidemic which generally appear too low for infants but too high for other ages.

Effect of Human Immunodeficiency Virus Treatment on Maternal Mortality at a Tertiary Center in South Africa: A 5-Year Audit

In Johannesburg, HIV remains the major cause of maternal mortality despite integration of antiretroviral treatment into prenatal services, and maternal health services should target barriers to uptake of HIV treatment and care.

Population-level associations between antiretroviral therapy scale-up and all-cause mortality in South Africa

The scale-up of antiretroviral therapy in South Africa was associated with a significant reduction in national all-cause mortality and the associated decrease in mortality the year after treatment reporting was seen in both adults and children, and men and women.

A Political and Social History of HIV in South Africa

The story of the HIV and AIDS response in South Africa over the past 5 years is one of great progress after almost a decade of complex and tragic denialism that united civil society in a way not seen since the opposition to apartheid.

HIV treatment in South Africa : the challenges of an increasingly successful antiretroviral programme : service delivery

This chapter examines the political policy programmatic and other issues surrounding the initiation and expansion of the ART programme in South Africa.

Income Status and Education as Predictors of HIV Transmission in South Africa

It is argued that income status and education act as risk factors for HIV through their effects on individual behaviour, while also being adversely impacted due to the occurrence of infection.



Estimation of adult antiretroviral treatment coverage in South Africa.

  • M. AdamL. Johnson
  • Medicine, Political Science
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
  • 2009
Significant progress has been made in expanding access to antiretroviral treatment in South Africa since 2004, but a substantial unmet need for treatment in adults remains.

Cost-Effectiveness of Highly Active Antiretroviral Therapy in South Africa

HAART is a cost-effective intervention in South Africa, and cost saving when HAART prices are further reduced, and the actual cost saving might have been underestimated if indirect costs were also included.

Management of HIV-infected children.

Paediatric HIV care has lagged behind that for adults in South Africa and relatively few children are benefiting from the services which should be available through the Comprehensive HIV and AIDS Care Management and Treatment Plan.

The cost-effectiveness of Antiretroviral Treatment in Khayelitsha, South Africa – a primary data analysis

BackgroundGiven the size of the HIV epidemic in South Africa and other developing countries, scaling up antiretroviral treatment (ART) represents one of the key public health challenges of the next

The survival benefits of AIDS treatment in the United States.

At least 3.0 million years of life have been saved in the United States as a direct result of care of patients with AIDS, highlighting the significant advances made in HIV disease treatment.

Integrating HIV Prevention and Treatment: From Slogans to Impact

The importance of integrating expanded care activities with prevention activities if there are to be long-term reductions in the number of new HIV infections and significant declines in AIDS mortality is demonstrated.

Potential Impact of Antiretroviral Therapy on HIV-1 Transmission and AIDS Mortality in Resource-Limited Settings

Antiretroviral therapy is predicted to have individual and public health benefits that increase with time and the proportion of infected persons treated, and the benefit can be lost by residual infectivity or disease progression on treatment and by sexual disinhibition of the general population.

Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire.

A strategy of trimethoprim-sulfamethoxazole prophylaxis and antiretroviral therapy, with the use of clinical criteria alone or in combination with CD4 testing to guide the timing of treatment, is an economically attractive health investment in settings with limited resources.

Model for simulation of HIV/AIDS and cost-effectiveness of preventing non-tuberculous mycobacterial (MAC)-disease

Because most HIV-infected patients die of diseases caused by opportunistic pathogens, the prevention of these infections is an important clinical issue. Cost-containment in the healthcare system is a